Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

Edwards Lifesciences (EW) recently secured the FDA’s approval for the EVOQUE tricuspid valve replacement system, a first-of-its-kind transcatheter therapy for the treatment of tricuspid regurgitation (TR). The system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.The latest development will strongly boost the company’s Transcatheter Mitral and Tricuspid ...